Phase I study of the combination of alpha-2 interferon and cisplatinum

C. Walsh; J. L. Speyer; J. Wernz; H. Hochster; H. Grossberg; A. Chachoua; P. Molinaro; M. Meyers; R. H. Blum

Phase I study of the combination of alpha-2 interferon and cisplatinum

C. Walsh, J. L. Speyer, J. Wernz, H. Hochster, H. Grossberg, A. Chachoua, P. Molinaro, M. Meyers, R. H. Blum

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 10⁶ U/m² alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m². Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 10⁶ U/m² of alpha-2 interferon 3 times weekly and 25 mg/m² of cisplatinum once weekly.

Original language	English
Pages (from-to)	11-15
Number of pages	5
Journal	Journal of Biological Response Modifiers
Volume	8
Issue number	1
State	Published - 1989
Externally published	Yes

Cite this

@article{aa948c1fa1144ec18c7daff5580aecc6,

title = "Phase I study of the combination of alpha-2 interferon and cisplatinum",

abstract = "Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 106 U/m2 alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 106 U/m2 of alpha-2 interferon 3 times weekly and 25 mg/m2 of cisplatinum once weekly.",

author = "C. Walsh and Speyer, {J. L.} and J. Wernz and H. Hochster and H. Grossberg and A. Chachoua and P. Molinaro and M. Meyers and Blum, {R. H.}",

year = "1989",

language = "English",

volume = "8",

pages = "11--15",

journal = "Journal of Biological Response Modifiers",

issn = "0732-6580",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Phase I study of the combination of alpha-2 interferon and cisplatinum

AU - Walsh, C.

AU - Speyer, J. L.

AU - Wernz, J.

AU - Hochster, H.

AU - Grossberg, H.

AU - Chachoua, A.

AU - Molinaro, P.

AU - Meyers, M.

AU - Blum, R. H.

PY - 1989

Y1 - 1989

N2 - Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 106 U/m2 alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 106 U/m2 of alpha-2 interferon 3 times weekly and 25 mg/m2 of cisplatinum once weekly.

AB - Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 106 U/m2 alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 106 U/m2 of alpha-2 interferon 3 times weekly and 25 mg/m2 of cisplatinum once weekly.

UR - http://www.scopus.com/inward/record.url?scp=0024544790&partnerID=8YFLogxK

M3 - Article

C2 - 2921608

AN - SCOPUS:0024544790

SN - 0732-6580

VL - 8

SP - 11

EP - 15

JO - Journal of Biological Response Modifiers

JF - Journal of Biological Response Modifiers

IS - 1

ER -

Phase I study of the combination of alpha-2 interferon and cisplatinum

Abstract

Fingerprint

Cite this